Key Takeaways
- India branded business delivered a standout quarter: Base business grew 19% vs IPM’s 12%, while the recently acquired JB portfolio added a 13% recovery and the Curation OTC business surged 34%.
- JB cost synergies are arriving faster than planned: The JB business posted a 35.3% EBITDA margin, up over 600 bps, pulling the synergy timeline forward and offsetting any transient integration revenue drag.
- Semaglutide leadership hit by a supply shock: A manufacturing partner issue knocked out ~20% of monthly SKU contribution, making the earlier ₹200–250 crore annualization target “definitely not going to be possible”; an alternate source is secured and relaunch is underway.
- International is a mixed bag with a clear US inflection: US will be profitable this year after five years of losses, while Germany remains “in the middle of the woods” and Brazil’s primary sales were dented by a one-time channel inventory correction.
- What to watch next quarter: The pace of semaglutide SKU share recapture, whether India’s IPM volume uptick sustains beyond a one-quarter phenomenon, and the first combined-entity margin guidance once integration settles.
India Branded Business: The Growth Engine Fires on All Cylinders
- Base business outperformance: 19% growth was driven by an unexpected IPM volume acceleration to 2%, a Q-ratio portfolio growing at 34%, and the culmination of 2–3 years of field force expansion that pushed the top 10 brands to 20%+ growth.
- Curation OTC scale-up: 34% growth came from continued ad spending and further field force expansion planned for the rest of FY27; management expects the high-growth trajectory to continue.
- Cardiac market leadership: Torrent plus JB now ranks first in the cardiac segment, the largest and among the fastest-growing in IPM, a milestone that strengthens the combined entity’s prescriber pull.
- Sustainability question: Management flagged that expansion-led growth may continue for the rest of the year but whether it continues next year is unknown, and the IPM volume uptick needs 2–3 more quarters of data to understand the real driver.
- Gross margin lift: Base business gross margin rose from ~76–76.5% last year to close to 78%, driven by annual April price increases, a higher branded business mix (76% vs 74% historically), and positive forex; management called up to 77% “definitely sustainable.”
Sudhir Menon: “As long as the supply situation remains the same for us and the competition, there's no additional bottlenecks that come up, my sense is that the market share should not change materially, materially from here.”
JB Pharma Integration: Synergies Arriving Early, Revenue Impact Contained
- Merger completed ahead of schedule: The merger closed on 8 July 2025, roughly six months earlier than initial perception, and system and business integration has been triggered with brand and division merging already underway.
- Cost synergies tracking ahead of plan: JB business EBITDA margin reached 35.3%, up over 600 bps, largely from cost synergies implemented sooner than expected; management confirmed the first-year synergy number is “definitely going to be above 100” versus the original ₹90 crore target, though they declined to give an exact figure.
- Revenue impact is minor and transient: Merging brands and divisions takes a few months, creating a minor revenue drag in some territories over the next 2–3 quarters, but management stressed no essential growth-spending has been cut and the drag will be nothing like the Q4 reset.
- Revenue synergies are a next-year story: Cross-sell potential, knowledge transfer, and field force combination in cardiac and gastro are promising, but management will only quantify revenue synergies after full integration, likely by year-end.
- Field force rationalization: Integration started in July; total MR count is expected to reduce even with additions to the base business, moving closer to ~9,000 in Q1 and staying around that level or slightly lower by year-end.
- JB India branded recovery: The business grew 13% following the Q4 operational reset, with field force attrition down to 16% in June from nearly 30% pre-acquisition; double-digit full-year revenue growth should still be possible.
Aman: “While this will not have an impact anything close to what was seen in Q4, there could be a minor and transient impact in revenues in some territories until the integration is completed over the next 2 to 3 quarters.”
Semaglutide: Supply Shock Derails the Trajectory, Not the Thesis
- What broke: An unforeseen supply issue with the manufacturing partner for the injectable product knocked out SKUs representing ~20% of total monthly semaglutide contribution; an alternate supply source is secured and all Samalex SKUs are expected back in market by end of August.
- Market share held despite the hit: Combined oral-plus-injectable market share was 36% in Q1, with oral alone holding 94% share in June even after a new competitor entered; management expects share to hold materially at current levels as long as no further supply bottlenecks arise.
- Annual guidance withdrawn: The earlier ₹200–250 crore annualization target is “definitely not going to be possible”; management will wait one more quarter to observe the relaunched SKUs’ share recapture trajectory before providing a revised annual number.
- Market sizing and realism: Management estimates the first-year market at ₹700–800 crore, maybe slightly bigger, but cautioned that the product carries side effects and patients who are not the right fit are likely to discontinue, implying the market will plateau rather than grow indefinitely.
- Brazil semaglutide: The regulator is expediting all semaglutide approvals and five came through the day before the call; management admitted losing first-mover advantage was “a bit of a miss” but remains confident of capturing double-digit market share given their physician community strength and track record.
Sudhir Menon: “Given now that we're faced with the situation, that's definitely not going to be possible. But we would rather wait for another quarter to see how our relaunch of the, the loss SKUs, how quickly they can regain share, and then we can get back with what the annual number could be.”
International Markets: US Turns the Corner, Germany and Brazil Weigh
| Market | Trend | Commentary |
|---|---|---|
| US | ▲ Inflecting | 23% constant currency growth from new launches achieving target share and one-time opportunities; 17 launches over 30 months contributing ₹2–2.5 crore largely compensate for price erosion; will be profitable this year after five years of losses. |
| Brazil | ▼ Headline soft, underlying strong | IQVIA secondary sales grew 19% vs market 4%, but primary sales were inferior due to a one-time channel inventory reduction as distributors sought extended credit amid rising interest rates; normalized mid-teens growth expected to return. |
| Germany | ▼ Still struggling | 9% constant currency decline from a twofold challenge: a prominent supplier contributing 10–15% of revenue is out of business, and the company still gets outbid in tenders despite cost-reduction efforts. |
| JB International | ▬ Recovering | Should recover post-changes; high single-digit to low double-digit constant currency growth for the full year should be possible. |
Sudhir Menon: “I can't say we are out of the woods in Germany. I would say right now we are, you know, still in the middle of the woods.”
Margins: Gross Margin Gains Fund the Investment Cycle
- Base business EBITDA margin: Improved 0.5% YoY to ~33.3%, as gross margin gains from price increases and mix shift were partially offset by higher Q1 branded business spending (typical seasonality) and forex-inflated expense lines.
- Annual margin commitment intact: Guidance for at least 0.5% improvement per year continues; Q1 delivered exactly that over last year’s 32.8%.
- Combined entity guidance deferred: Management will wait one more quarter until the combined entity settles before providing full-year margin guidance for the merged Torrent-plus-JB entity.
- JB margin trajectory: Should improve incrementally every quarter from the 35.3% Q1 level as cost synergies continue to phase in; manufacturing synergies are being taken up in the second phase and remain unquantified.
Capital Allocation: India First, Patience on M&A
- Near-term priority is integration: Management will wait at least another 12–18 months for comfort that JB integration has gone as planned before looking at the next opportunity.
- India-first preference: If the same-size opportunity exists in India versus international, it will always be India first regardless of size; in the absence of Indian market opportunities, mid-sized international acquisitions may be considered.
- Leverage discipline: Management would not want to be above 3x or 3.5x net debt-to-EBITDA for any opportunity considered.
Sudhir Menon: “Our preference is that if we have the same size opportunity in front of us in India versus international, regardless of how big or small, it will always be India first.”
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| JB India branded growth | Double-digit revenue growth for full year | FY27 |
| JB International growth | High single-digit to low double-digit constant currency growth | FY27 |
| Integration revenue impact | Minor and transient; normalization expected | By Q4 FY27 |
| Cost synergies | First-year number “definitely going to be above 100” (vs original ₹90 crore); incremental quarterly improvement | FY27 |
| Base business EBITDA margin | At least 0.5% improvement per year over prior year | FY27 |
| US profitability | Will be profitable this year, at least will not subtract from bottom line | FY27 |
| Semaglutide annual guidance | Revised number to be provided after observing relaunched SKU share recapture | Next quarter |
| Combined entity margin guidance | Full-year margin guidance for merged entity | Next quarter |
| Capital allocation | No next opportunity considered until JB integration comfort is achieved | 12–18 months |
| Leverage ceiling | Not above 3x–3.5x net debt-to-EBITDA | Ongoing |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated revenue | ₹4,921 cr, up 55% YoY |
| Operating EBITDA | ₹1,664 cr, up 61% YoY |
| Operating EBITDA margin | 33.8% |
| Base business revenue growth | 17% YoY |
| Base business operating EBITDA | ₹1,240 cr, up 20% YoY |
| Base business EBITDA margin | 33.3% |
| Base business gross margin | ~78%, versus ~76–76.5% last year |
| India base business revenue | ₹2,157 cr, 19% growth vs IPM growth of 12% |
| India base business volume growth | 5.1% vs IPM volume growth of 2% |
| India base business price growth | 7.7% vs IPM price growth of 5.8% |
| India base business new product contribution | ~6% vs IPM new product growth of 3.8% |
| JB business revenue | ₹1,201 cr, up 10% YoY |
| JB business EBITDA margin | 35.3%, improvement of more than 6% YoY |
| JB India branded business growth | 13% |
| JB international business growth | 12% |
| Brazil constant currency revenue | BRL 14.7 cr, 3% YoY growth; IQVIA growth at 19% |
| Brazil generics share of sales | ~22% |
| US constant currency revenue | $44 million, up 23% YoY |
| Germany constant currency revenue | €2.9 cr, down 9% YoY |
| Curation business growth | 34% |
| Semaglutide franchise India Q1 market share | 36% (oral and injectable combined) |
| Semaglutide oral market share in June | 94% |
| Semaglutide combined Q1 sales | ₹50 cr |
| Semaglutide full-year target | ₹250 cr (on track before supply issue) |
| Combined field force strength | 9,400 (base: 7,200, JB: 2,200) |
| Combined PCPM | Just over ₹10 lakhs |
| JB field force attrition | 16% in June, down from nearly 30% pre-acquisition |
| Net debt to EBITDA | 2.07x (on underlying combined EBITDA) |
| First-year synergy target | Above ₹100 cr (original target ₹90 cr) |
| Brands above ₹100 cr | 28 |